Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Gastrointestinal 1

Conditions

Gastrointestinal Stromal Tumors 1

Interventions

Fluorouracil 309Oxaliplatin 260Leucovorin 234Capecitabine 198Irinotecan 147Gemcitabine 128Cisplatin 126Bevacizumab 119Radiotherapy 72Paclitaxel 64Folfox protocol 56Cetuximab 56Drug Therapy 46Sorafenib 45Docetaxel 42S 1 (combination) 40Chemotherapy, Adjuvant 38Neoadjuvant Therapy 37pembrolizumab 36130-nm albumin-bound paclitaxel 29Surgical Procedures, Operative 27regorafenib 25lenvatinib 24XELOX 24Radiation 24Panitumumab 24Nivolumab 23atezolizumab 22Carboplatin 22trifluridine tipiracil drug combination 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × tanespimycin × Gastrointestinal × Clear all
NCT00688766 2012-12-11

Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib

Infinity Pharmaceuticals, Inc.

Phase 3 Terminated
47 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡